Mental health is a public health issue for European young people. The Global Burden of Disease (GBD) Study 2019 provides internationally comparable information on trends in the health status of populations and changes in the...
Although more than 1 in every 3 US individuals will develop a substance use disorder in their lifetime, relatively little is known about the long-term patterns of substance use disorder symptoms from adolescence through adulthood.
The EMCDDA launched a new Prevention toolkit, bringing together all of its key prevention-related materials to date. Part of the agency’s toolkit series, this new resource is aimed at anyone involved in shaping decisions, opinions and...
Focusing treatments on specific settings where problems may develop is an important approach to implementing health and social responses to drug problems. As a result, the EMCDDA's Health and social solutions to drug problems: a European...
Alcohol-related harm is a growing concern globally and particularly in West Africa. However, tools for assessing the readiness for prevention of alcohol-related harm in low-resource settings have been lacking. This research explores the...
The analysis of municipal wastewaters for drugs and their metabolic products to estimate community consumption is a developing field, involving scientists working in different research areas, including analytical chemistry, physiology...
Today, the European Commission has adopted measures to control two harmful new psychoactive substances (NPS) across the EU. The substances in question — 3-methylmethcathinone (3-MMC) and 3-chloromethcathinone (3-CMC) — are both synthetic...
